• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lucid Diagnostics Inc (NQ: LUCD )

    1.040 +0.040 (+4.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lucid Diagnostics Inc

    < Previous 1 2 3 4 Next >
    Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
    From Lucid Diagnostics Inc.
    Via Business Wire
    PAVmed Provides Business Update and Third Quarter 2022 Financial Results
    From PAVmed Inc.
    Via Business Wire
    Earnings Scheduled For May 11, 2022
    Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
    Via Benzinga
    Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
    From Lucid Diagnostics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
      
    Via Benzinga
    Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
    From Lucid Diagnostics Inc.
    Via Business Wire
    Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
    From Lucid Diagnostics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
    Via Benzinga
    Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
    From Lucid Diagnostics Inc.
    Via Business Wire
    PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
    From PAVmed Inc.
    Via Business Wire
    Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
    From Lucid Diagnostics Inc.
    Via Business Wire
    How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock?
    Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand... 
    Via Benzinga
    PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
    From PAVmed Inc.
    Via Business Wire
    Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
    From Lucid Diagnostics Inc.
    Via Business Wire
    10 Biggest Price Target Changes For Tuesday
    BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. 
    Via Benzinga
    Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
    From Lucid Diagnostics Inc.
    Via Business Wire
    Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
    From Lucid Diagnostics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding... 
    Via Benzinga
    PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
    From Lucid Diagnostics Inc.
    Via Business Wire
    PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
    From Lucid Diagnostics Inc.
    Via Business Wire
    PAVmed Appoints Shaun O’Neil as Chief Operating Officer
    From PAVmed Inc.
    Via Business Wire
    Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
    From PAVmed Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.